Table 1.
Mouse models of MDS.
| Genetic aberrations | Techniques | Reference |
|---|---|---|
| Gene expression | ||
| Pten/Ship deletions | Pten haploinsufficient, Ship knockout | (11) |
| Evi1 overexpression | Retroviral transduction | (12) |
| Npm1 deletion | Npm1 haploinsufficient | (13, 14) |
| Dido deletion | Knockout | (15) |
| NUP98-HOXD13 fusion | Transgenic expression (Vav promoter) | (16–19) |
| SALL4B | Transgenic expression (CMV promoter) | (9) |
| Bcl2/mutant Nras | Transgenic co-expression (tTA, MRP8 promoters) | (20) |
| Arid4a | Knockout | (21) |
| Polg | Knock-in of mutant (PolgA/A) | (10) |
| MLL fusions | Retroviral transduction | (22) |
| Recurrent mutations | ||
| Transcription factors | ||
| RUNX1 | Retroviral expression (D171N, S291fs) | (23) |
| Bcor | Loss-of-function mutation | (24) |
| Epigenetic modifiers | ||
| Dnmt3a | Mx1-Cre mediated ablation | (25) |
| Tet2 | Tet2:nlacZ/nGFP knockin, which results in nlacZ transcription | (25) |
| Ezh2 | Rosa26:Cre-ERT mediated ablation, followed by HSPC transplant | (26) |
| Axsl1 | Homozygous/heterozygous Asxl1:nlacZ/nGFP knockin | (27) |
| Splicing factors | ||
| Srsf2 | Mx1-Cre mediated heterozygous expression of Srsf2P95H | (28) |
| U2af1 | Doxycycline inducible heterozygous expression of U2af1S34F | (29) |
| Sf3b1 | Mx1-Cre mediated heterozygous expression of Sf3b1K700E | (30) |
| Zrsr2 | Mx1-Cre mediated ablation | (28) |
| Chromosomal aberrations | ||
| del(5q) | Deletion of Cd74-Nid67 interval | (31) |
| BMME dysfunctions | ||
| Dicer1 | Osx-Cre mediated ablation | (32) |
| Sbds | Osx-Cre mediated deletion | (32, 33) |
| S100A9 | Transgenic overexpression | (34) |